Search

ESH-EBMT-EHA-IPIG 3rd Translational Research Conference

ESH-EBMT-EHA-IPIG 3rd Translational Research Conference on Bone Marrow Failure and Leukaemia Predisposition Syndromes

Date: November 15-17, 2024
Location: Paris, France

Chairpersons: Carmem Bonfim, Tim Brümmendorf, Antonio Risitano, Sharon Savage
Scientific Committee: Beatrice Drexler, Carlo Dufour, Morag Griffin, Régis Peffault de Latour

With the support of the Severe Aplastic…

Chairs and Members

ChairGiancarlo Castaman, University of Florence - Careggi University Hospital, Florence (Italy)

Co-chairAnna Falanga, University of Milan Bicocca and Hospital Papa Giovanni XXIII, Bergamo (Italy)

SWG Steering Committee
Ajay K Kakkar, Thrombosis Research Institute, London (United Kingdom)
Augusto Federici, University of Milan, University Hospital Luigi…

Corporate Sponsor Program

View the EHA Ranking 2025

"Alone we can do so little; together we can do so much.

Priority Points System

The Priority Points System is designed to recognize sponsors’ investment and continuous support for EHA activities, and are allocated for each sponsorship program and/or item.

Research & Mentoring

One of EHA’s key pillars is investing in future leaders in hematology.

EHA-SfPM Precision Medicine Meeting

EHA and SfPM (Society for Functional Precision Medicine) are proud to present the first joint meeting on Precision Medicine.

Registration & Accommodation

Registration is now closed. Registration fee includes:

Access to the scientific and educational sessions of the meeting
Networking opportunities during breaks and welcome reception
Catering during meeting hours incl.

How to apply

The CRTH 2025 call for applications is now closed. Timelines
Application CRTH 2025
Deadline: September 24, 2024 (15:00 CEST)

Notification
November 2024

Questions: training@ehaweb. orgDownload the Signature letter template.

Adolescents and young adults (AYA)

Spotlight on AYAAdolescents and young adults (AYA) with hematologic diseases are a unique group with special characteristics and needs. In recent years, the challenges related to the management of AYA (particularly in relation to cancer) have increasingly been recognized.